Nanoparticles for Thrombolytic Therapy in Ischemic Stroke: A Systematic Review and Meta-Analysis of Preclinical Studies
Pharmaceutics,
Journal Year:
2025,
Volume and Issue:
17(2), P. 208 - 208
Published: Feb. 6, 2025
Background:
Recombinant
tissue
plasminogen
activator
(rtPA)
remains
the
standard
thrombolytic
treatment
for
ischemic
stroke.
Different
types
of
nanoparticles
have
emerged
as
promising
tools
to
improve
benefits
and
decrease
drawbacks
this
therapy.
Among
them,
cell
membrane-derived
(CMD)
nanomedicines
gained
special
interest
due
their
capability
increase
half-life
particles
in
blood,
biocompatibility,
thrombus
targeting.
In
order
update
evaluate
efficacy
these
nanosystems,
we
performed
a
meta-analysis
selected
vivo
preclinical
studies.
Methods:
Preclinical
studies
stroke
models
been
identified
through
search
Pubmed
database.
We
included
rtPA-nanoparticles,
which
assessed
infarct
volume
and/or
neurological
improvement.
Nanosystems
were
compared
with
free
(non-encapsulated)
rtPA
treatment.
Standardized
mean
differences
computed
pooled
estimate
effect
sizes
lesion
volumes
scores.
Subgroup
analyses
by
risk
bias,
type
nanoparticle,
time
administration
also
performed.
Results:
A
total
18
publications
meta-analysis.
This
was
based
on
defined
inclusion
criteria.
Our
analysis
revealed
that
rtPA-nanoparticles
improved
both
scores
Moreover,
CMD
showed
better
evolution
other
nanoparticles.
Funnel
plots
exhibited
asymmetry
publication
bias.
Heterogeneity
generally
high,
funnel
plot
Egger
test
some
evidence
bias
did
not
achieve
statistical
significance
trim-and-fill
analysis.
Conclusions:
rtPA-encapsulating
nanosystems
shown
scales
treatment,
had
greatest
beneficial
effect.
Language: Английский
Serum Proteomic Markers in Patients with Systemic Sclerosis in Relation to Silica Exposure
M. Freire,
No information about this author
B. Sopeña,
No information about this author
Susana B. Bravo
No information about this author
et al.
Journal of Clinical Medicine,
Journal Year:
2025,
Volume and Issue:
14(6), P. 2019 - 2019
Published: March 16, 2025
Background:
Systemic
sclerosis
(SSc)
is
a
multisystem
autoimmune
disease
characterised
by
fibrosis,
vasculopathy,
and
immune
dysfunction.
Silica
exposure
has
been
associated
with
more
aggressive
phenotype
of
the
disease,
including
diffuse
cutaneous
involvement
interstitial
lung
disease.
This
study
aims
to
identify
proteomic
differences
between
SSc
patients
exposed
silica
those
not
silica.
Methods:
An
observational
32
(11
silica-exposed
21
non-exposed)
was
performed,
occupational
history
quantitative
analysis
using
SWATH-MS
mass
spectrometry.
Differentially
expressed
proteins
were
analysed,
functional
pathway
enrichment
performed.
Results:
Eight
showed
significant
groups,
all
reduced
levels
in
patients:
adiponectin,
immunoglobulins
(IGLV3-19,
IGLV2-18),
complement
C2,
alpha-2-macroglobulin,
vitronectin,
cytoplasmic
actin
2,
pigment
epithelium-derived
factor.
Alterations
pathways
related
fibrinolysis,
activation,
inflammation
highlighted,
suggesting
that
may
influence
pathogenesis
worsen
its
clinical
course.
Conclusions:
supports
hypothesis
only
triggering
factor
for
SSc,
but
also
modulating
progression
through
inflammatory,
procoagulant,
fibrotic
pathways.
The
identification
biomarkers
could
contribute
phenotypic
classification
development
personalised
therapies.
Future
studies
should
expand
cohort
further
investigate
mechanisms
these
SSc.
Language: Английский